Ignite Creation Date:
2024-05-06 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06153251
Status:
RECRUITING
Last Update Posted:
2024-05-10
First Post:
2023-11-22
Brief Title:
A Study to Assess BMS-986453 in Participants With Relapsed andor Refractory Multiple Myeloma
Sponsor:
Juno Therapeutics Inc a Bristol-Myers Squibb Company
Organization:
Juno Therapeutics Inc a Bristol-Myers Squibb Company
Study Overview
Official Title:
A Phase 1 Open-Label Dose-Finding Study of BMS-986453 Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells in Participants With Relapsed andor Refractory Multiple Myeloma
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess BMS-986453 in participants with relapsed andor refractory multiple myeloma RRMM
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None